pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,388 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1212Endpoints919BioPharma Dive354BioSpace335Fierce Biotech316onclive165raps111globenewswire health
therapy area
allOncology8159Rare Disease1937Cardiology1879Immunology1565Hematology1354Pulmonology1264Vaccines
  • FDA gives modest backing to Moderna’s flu vaccine, noting efficacy questions but no major concerns
    The FDA released briefing documents ahead of an advisory committee meeting on Moderna’s seasonal influenza vaccine. The agency’s assessment was described as tepid, highlighting some questions abou…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
  • FDA approves Colorado plan to import lower-cost drugs from Canada
    The U.S. Food and Drug Administration issued a letter confirming that Colorado may move forward with a pilot program to bring prescription medicines from Canada. The proposal aims to lower drug co…
    Endpoints · 2mo agoRegulatoryPositive↗ source
← prev
page 42 of 56
next →
73
fda recalls71
fda medwatch63
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain503
Endocrinology & Metabolism495
Infectious Disease457
  • Edgewise Therapeutics moves heart disease drug into Phase 3 after updated Phase 2 data
    Edgewise Therapeutics announced on June 16, 2026 that it will advance its investigational therapy for a genetic heart disease into a registrational Phase 3 trial. The decision follows an updated a…
    Endpoints · 2mo agoPositive readoutPositive↗ source
  • Eli Lilly acquires another pain biotech, its 11th deal this year, as FDA eyes decision on once‑weekly PrEP pill
    Eli Lilly announced the purchase of an Austin, Texas‑based pain biotechnology company, marking the 11th acquisition the Indianapolis‑based firm has completed in 2026. The deal expands Lilly's portf…
    Endpoints · 2mo agoDealNeutral↗ source
  • Health groups accuse HHS of rushing reinstatement of CDC vaccine advisory panel
    A coalition of health organizations has publicly charged the U.S. Department of Health and Human Services with attempting to accelerate the return of the CDC's Advisory Committee on Immunization Pr…
    Endpoints · 2mo agoRegulatoryNegative↗ source
  • UCSF spinout Kopra Bio secures $9.1M to advance virus therapy for glioblastoma in China
    Kopra Bio, a biotechnology company spun out of the University of California, San Francisco, announced it has raised $9.1 million in financing. The capital will be used to move its experimental viru…
    Endpoints · 2mo agoDealPositive↗ source
  • Be Bio halts hemophilia B cell-editing therapy trial
    Be Bio announced that it has terminated its clinical study of a hemophilia B therapy that used gene-editing of a patient’s own cells. The termination was recorded in a federal clinical-trials regi…
    Endpoints · 2mo agoNegative readoutNegative↗ source
  • OpenLoop Health says it can launch a virtual GLP-1 prescribing service in 24 hours
    OpenLoop Health says it can set up a telehealth operation that can prescribe GLP-1 medicines within a day. The company provides the medical‑group infrastructure that powers multiple virtual care p…
    Endpoints · 2mo agoNeutral↗ source
  • CMS proposes rule to close Medicare negotiation loophole for biologics
    CMS announced a proposed policy change that would clarify how the Centers for Medicare & Medicaid Services groups products for price negotiations under the Inflation Reduction Act. The rule target…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • FDA says it will maintain Makary’s focus on clinical trials, rare diseases and China despite leadership exits
    The Food and Drug Administration announced that, even after the recent resignations of Commissioner Marty Makary and the heads of its drug and biologics centers, it will keep pursuing the policy ag…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Takeda releases additional Phase 3 data to bolster its orexin program amid new competition
    Takeda announced new results from its two Phase 3 trials of an orexin‑targeting therapy. The data are intended to demonstrate the drug’s efficacy and safety, reinforcing Takeda’s claim of market‑l…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Elicio Therapeutics’ KRAS pancreatic cancer vaccine fails in Phase 2, stock drops sharply
    Elicio Therapeutics reported that its KRAS‑targeted vaccine for pancreatic cancer did not improve patient outcomes in a mid‑stage (Phase 2) trial. The study results were released in a company state…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Gan & Lee reports positive Phase 3 obesity trial results; J&J shares multiple myeloma data
    Gan & Lee Pharmaceuticals, a China‑based insulin specialist, announced topline results from its Phase 3 obesity trial, indicating a successful outcome. The company said the study met its primary e…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Neumora Therapeutics halts lead depression drug after two more Phase 3 failures, plans 35% staff cuts
    Neumora Therapeutics announced that its lead depression candidate will be discontinued after it did not meet primary endpoints in two additional Phase 3 trials. The company said the data were consi…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • HMNC Brain Health raises $50M Series B to advance two depression drugs
    HMNC Brain Health announced it has closed a $50 million Series B financing round. The capital will be used to move two depression drug candidates into mid-stage clinical trials. The round was led…
    Endpoints · 3mo agoDealNeutral↗ source
  • Lilly showcases Jaypirca combination data in CLL at EHA26, debuting results from Ajax acquisition
    Eli Lilly highlighted new blood‑cancer data at the European Hematology Association meeting in Stockholm. The company presented early clinical results for its Jaypirca therapy combined with the stan…
    Endpoints · 3mo agoNeutral↗ source
  • Six Biopharma Leaders Drive LGBTQ+ Inclusion Amid Rising Anti-LGBTQ Legislation
    Six executives are spearheading initiatives to improve LGBTQ+ inclusion across the biopharmaceutical sector. Their work focuses on creating supportive policies, training programs, and community out…
    Endpoints · 3mo agoNeutral↗ source
  • Biopharma launches nominations for 2025 pay report and highlights Parabilis record IPO
    Endpoints Weekly announced the start of nominations for its eighth annual Women in Biopharma report, aiming to feature 20 distinguished women across science, leadership, and entrepreneurship. The…
    Endpoints · 3mo agoDealNeutral↗ source
  • Merck's Welireg and Keytruda combo receives FDA approval for adjuvant kidney cancer therapy
    Merck announced that its combination of the oral VEGFR inhibitor Welireg and the immunotherapy Keytruda has been cleared by the U.S. Food and Drug Administration. The clearance applies to patients…
    Endpoints · 3mo agoApprovalPositive↗ source
  • GSK completes $10.6 billion acquisition of Nuvalent, the largest in its history
    GSK announced it has completed a $10.6 billion purchase of Nuvalent, marking the biggest deal the company has ever undertaken. The transaction was disclosed on Tuesday and values Nuvalent at $124…
    Endpoints · 3mo agoDealNeutral↗ source
  • Enliven Therapeutics raises $400M as Jazz's Zepzelca misses confirmatory trial
    Enliven Therapeutics, a biotech based in Burlingame, California, announced that it priced a public offering of its common stock that raised about $400 million. The capital raise follows the compan…
    Endpoints · 3mo agoDealNeutral↗ source
  • Novo's M&A head joins Forbion as Perrigo CEO steps down over conduct concerns
    Novo's senior M&A executive has left the company to take a role at Dutch investment firm Forbion. Forbion, which manages a portfolio of biotech companies, has been active in M&A and aims to increa…
    Endpoints · 3mo agoNeutral↗ source
  • Amgen seeks FDA review of Tavneos to determine continued market availability
    Amgen has formally asked the U.S. Food and Drug Administration to re-examine the data supporting its drug Tavneos (avacopan). Tavneos is indicated for a rare form of vasculitis and the request sig…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Eli Lilly backs health-tech startup Abridge to expand clinical trial recruitment
    Eli Lilly’s venture arm has made an investment in Abridge, a health‑technology company that is moving into the clinical trial recruitment space. The funding is intended to help Abridge broaden its…
    Endpoints · 3mo agoDealPositive↗ source
  • Sciwind Biosciences seeks additional partners for obesity drug ecnoglutide after deals with Pfizer and Verdiva Bio
    Sciwind Biosciences, a Chinese biotech, has licensed its GLP-1 obesity candidate ecnoglutide to two Western companies. The first agreement grants Pfizer rights to develop and commercialize the dru…
    Endpoints · 3mo agoDealPositive↗ source